Novartis reports positive results from Phase III multiple sclerosis trial
According to Novartis, these data reinforce previous results from the Transforms study announced in December 2008 showing that the relapse rate at one year was 52% lower in
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
Definitive LE is a prospective, multi-center, single-arm study to evaluate the intermediate and long-term effectiveness of stand-alone SilverHawk plaque excision therapy for endovascular treatment of lower extremity peripheral
Impulse Monitoring will provide Nash Health Care with comprehensive intraoperative neurophysiological monitoring (IONM) services, including real-time professional oversight by experienced physicians. IONM assesses neurological function involving the brain,